SB 220025

SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC₅₀ = 60 nM). SB 220025 also inhibits p56^Lck and PKC with IC₅₀ values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation^[1][2]. In Vitro:SB 220025 (20 μM; 6 h) markedly reduces IL-8 gene expression in response to globular adiponectin (gAd) in HUVEC cells^[1]. In Vivo:SB 220025 (3-50 mg/kg; p.o.; single) inhibits inflammatory cytokine production in vivo^[2].
SB 220025 (5, 30, 50 mg/kg; i.p.; b.i.d.) inhibits angiogenesis in the murine air pouch granuloma model^[2].
SB 220025 (30 mg/kg; p.o.; twice a day for 3, 5, 7 or 14 days) prevents the increase in angiogenesis that occurs after day 3 in murine air pouch angiogenesis model^[2].
SB 220025 (50 mg/kg; p.o.; b.i.d.; 10 days) effectively blocks the progression of arthritis in a chronic inflammatory disease model^[2].